• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Prostate cancer: PSA test skipping advice creates outrage | MassDevice.com On Call

Prostate cancer: PSA test skipping advice creates outrage | MassDevice.com On Call

May 22, 2012 By MassDevice staff

MassDevice On Call

MASSDEVICE ON CALL — A nationwide urologists lobbying group largely discredited guidance from a U.S. Preventative Services Task Force recommending that physicians set aside a commonly used prostate cancer screening tool.

Known as the prostate-specific antigen test, or PSA, the tool may pose more risks than benefits, according to the panel.

"Many people have a blind faith in early detection of cancer and subsequent aggressive medical intervention whenever cancer is found," American Cancer Society chief medical officer Dr. Otis Brawley wrote in an accompanying commentary on the panel’s decision. "There is little appreciation of the harms that screening and medical interventions can cause."

The panel was generally concerned about the dangers of aggressive prostate cancer treatment in patients who are asymptomatic and whose cancer may have remained neutral without intervention.

The Large Urology Group Practice Assn. expressed "outrage" at the USPSTF’s recommendation, warning that "failing to detect cancer early will create a public health catastrophe in 5-10 years," according to a press release.

"USPSTF clearly ‘cherry-picked’ data to support what can only be viewed as a pre-conceived bias against screening," LUGPA president Dr. Deepak Kapoor said in a prepared statement. "The task force did not include any physician who treats prostate cancer, and ignored credible studies and epidemiological data demonstrating a significant survival advantage to early detection…we are not detecting more cancer; we are detecting cancer earlier and saving lives."

Early results presented at the European Assn. of Urology this month from a long-term study of prostate cancer patients support the USPSTF’s decision, suggesting that surgical prostatectomy barely increased the likelihood for survival in patients with low-risk tumors.

 Health care cost spikes have little to do with waste, study shows
A study combining health data from 4 of the U.S.’s largest insurers found that, although the number of health care services provided decreased, the cost for individual services rose, posing a challenge to those who argue that cutting down on unnecessary services can help stem the ever-increasing cost of health care.
Read more

 Wearable cancer-disrupter proves as good as chemo
Novocure’s wearable, portable NovoTTF cancer-disrupting device proves as good as chemotherapy in extending overall survival for advanced brain cancer patients, with minimal side effects and far fewer impacts to a patient’s quality of life.
 
Read more

 Lower-risk sigmoidoscopy just as good as colonoscopy in preventing colon cancer deaths
A lower-risk colon examination using a sigmoidoscope was just as good at detecting colorectal cancer and reducing mortality rates as the more commonly used colonoscopy, according to the National Institutes of Health.  
Read more

 Bariatric surgery may have positive effects on blood sugar levels
A novel, experimental form of bariatric surgery helped control blood sugar levels in rats with diabetes in a study conducted at the Toronto General Hospital Research Institute.  
Read more

Filed Under: Diagnostics, News Well, Oncology Tagged With: American Cancer Society, Clinical Trials, Large Urology Group Practice Assn., National Institutes of Health (NIH), NovoCure, On Call, Prostate, U.S. Preventive Services Task Force (USPSTF)

In case you missed it

  • 3M Health Care Business president is leaving this year
  • Device developer SeaStar Medical hires chief medical officer
  • AccuPulse raises $10M Series A
  • Exactech announces first U.S. surgeries with its nex-gen laser cage glenoid
  • Baxter expects sales growth momentum through 2025
  • Vivera picks up new patent for electronic dose-controlled drug delivery devices
  • Stryker launches dynamic compression system for foot, ankle applications
  • Entegris opens Life Sciences Technology Center in Massachusetts
  • Glucose monitor maker Know Labs expands leadership team
  • inHeart wins FDA clearance for 3D cardiac modeling software
  • How Glytec is advancing insulin management in the hospital
  • Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
  • FDA clears RapidAI’s pulmonary embolism triage platform
  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive

RSS From Medical Design & Outsourcing

  • 3M Health Care Business president is leaving this year
    3M Health Care Business Group President Mojdeh Poul will retire from the company on July 1, 2022. Poul joined Maple Grove, Minnesota-based 3M (NYSE:MMM) in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M… […]
  • Iterative Scopes announces positive data in Skout AI colonoscopy algorithm clinical trial
    Iterative Scopes this week announced positive trial data in a study of its colorectal cancer screening algorithm, Skout. Cambridge, Massachusetts-based Iterative Scopes designed Skout as a computer-aided device (CADe) that uses artificial intelligence and computer vision technology to detect suspicious tissue and provide real-time feedback for gastroenterologists performing the procedure. Get the full story on… […]
  • Device developer SeaStar Medical hires chief medical officer
    SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1. Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year. SeaStar is set to go public in… […]
  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]
  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS